Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06821802

Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis

Led by University Hospital, Basel, Switzerland · Updated on 2025-07-10

70

Participants Needed

1

Research Sites

102 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.

CONDITIONS

Official Title

Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients with confirmed syndrome of inappropriate antidiuresis (SIAD) during hospital stay or screening
  • Plasma sodium concentration below 135 mmol/L
  • Plasma osmolality below 300 mOsm/kg
  • Urine osmolality above 100 mOsm/kg
  • Urine sodium concentration above 30 mmol/L
  • Clinical euvolemia with no signs of low or high blood volume
Not Eligible

You will not qualify if you...

  • Allergies to lactose, milk protein, soy, nuts, or protein supplement components
  • Inborn metabolic disorders affecting carbohydrate, lipid, or protein metabolism
  • Severe symptomatic hyponatremia requiring 3% sodium chloride or intensive care
  • Treatment within past 5 days with SGLT2 inhibitors, vaptans, or oral urea
  • Uncontrolled severe hypothyroidism or adrenal insufficiency
  • Kidney function with eGFR below 45 mL/min/1.73 m² or end-stage renal disease requiring dialysis
  • Severe liver impairment or advanced liver disease with encephalopathy, cirrhosis Child C, or decompensation
  • Pregnancy, breastfeeding, or plans to become pregnant during study
  • Receiving end-of-life care
  • Inability to consent or follow procedures due to language, psychological issues, dementia, etc.
  • Current treatment with thiazide diuretics unless stopped at least 48 hours before inclusion
  • Post-randomization exclusion: type 1 diabetes or uncontrolled type 2 diabetes with HbA1c over 8.0%

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital Basel

Basel, Switzerland, 4031

Actively Recruiting

Loading map...

Research Team

M

Mirjam Christ-Crain, Prof. MD

CONTACT

C

Cemile Bathelt

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here